Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Summary

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2017-05-24

Primary completion

2026-11-21

Completion

2026-11-21

Drugs

Indications